drugset / Trial / NCT01534273
A Study of LY2886721 in Healthy Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
The purpose of this phase I study in healthy participants will be to evaluate the safety and tolerability of LY2886721 single and multiple doses, to evaluate how the body handles the drug, and to evaluate the drug's effect on the body.
Timeline
- Start
- 2012-02
- Primary completion
- 2012-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY2886721 | Small molecule | 35 mg | Oral |
| Subject | LY2886721 | Small molecule | 70 mg | Oral |
| Subject | LY2886721 | Small molecule | 140 mg | Oral |
Indications
No indication recorded.